• Home     Staff and Contacts     What We Do     About New Zealand     News and Events     Centre Partners     Get Involved     Int'l Relations Office PKU
  • New Zealand Centre Visiting Fellow Professor Christian Hartinger

    17/07/2015 – Academic Seminar and Open Lecture by New Zealand Centre Visiting Fellow, Professor Christian Hartinger of The University of Auckland

    Professor Christian Hartinger prepared the following lectures as part of a Visiting Fellowship with the New Zealand Centre. If you are a member of the academic staff from any of our eight partner institutions and you are interested in attending a fellowship at Peking University, get in touch with our liaison officers to learn more about the application process. Visiting fellowships for New Zealand academics are held year-round at Peking University, across a broad range of departments, forming a significant contribution to the advancement of academic exchange between China and New Zealand.

    Christian Hartinger is an Associate Professor at the University of Auckland (New Zealand) in Chemical Sciences at the Faculty of Science. He has been awarded one of the 2015 Visiting Fellowships to the New Zealand Centre at Peking University. In the month of July he will host a Seminar and Open lecture at Peking University. Please see below for details.

    SEMINAR: 27/07/2015 “Bioorganometallics in Anticancer Drug Development: Toward More Selective Chemotherapeutics”

    Venue: Peking University Health Centre Campus

    Host: Professor Xiaoda Yang, State Key Laboratories on Natural and Mimetic Drugs and Department of Chemical Biology

    In this seminar Professor Hartinger will discuss Bioorganometallic chemistry: ‘Bioorganometallic chemistry is a thriving field of research and in particular the development of anticancer drugs based on organometallic moieties has received a lot of attention in recent years and several promising drug candidates have been developed. It has been shown that small modifications have a big impact on the mode of action and in particular the activity profile. Such changes have led to compounds with activity against the primary tumours and metastases. The talk will highlight the most recent advances in the field and will be complemented by the major contributions of my research group, in particular new chemical entities and mode of action studies’ – Professor Christian Hartinger.

    OPEN LECTURE: 29/07/2015 “Shifting paradigms from organic pharmacophores to medicinal inorganic chemistry in drug development”

    Venue: College of Chemistry and Molecular Engineering, Peking University

    Host: Professor Chen Peng

    Organizers: College of Chemistry and Molecular Engineering, Peking University

    In this lecture Professor Hartinger will discuss developments in the field of treatment of cancer: ‘Although medicinal chemistry is widely dominated by organic molecules, some of the most important drugs widely used in the treatment of, for example, cancer but also in diagnosis have as the central component a metal ion. This public lecture will review the various roles of metal ions in medicine and in particular in the treatment of cancer and will highlight some of the major developments since the discovery of cisplatin and its rise to one of the leading cancer drugs. There are many exciting discoveries in this field and some of the most promising concepts and approaches with compounds undergoing currently clinical trials will be presented together with a discussion on the potential for future clinical development'.

    About Professor Christian Hartinger

    Professor Hartinger’s areas of expertise are in “Medicinal Chemistry, Biological Inorganic Chemistry, Coordination and Organometallic Chemistry, Development of Anticancer Compounds, Bioanalytical Chemistry (Mass Spectrometry, Capillary Electrophoresis, Hyphenated Systems)”. Professor Hartinger is a member of a number of committees and professional groups both in Austria and New Zealand. His current research observes “bioorganometallics with a particular interest in the synthesis of anticancer active mono-, di- and trinuclear compounds with (thio)pyr(id)onato ligands".

    Click here to read more news and events stories...